News
HKMPF
19.07
NaN%
--
Hikma advances $250m share buyback, cancels repurchased stock
TipRanks · 9h ago
Weekly Report: what happened at HKMPF last week (0720-0724)?
Weekly Report · 11h ago
Weekly Report: what happened at HKMPF last week (0713-0717)?
Weekly Report · 07/20 09:11
Hikma Advances $250 Million Share Buyback, Cuts Share Count
TipRanks · 07/20 08:27
Hikma Pharmaceuticals initiated with a Buy at Citi
TipRanks · 07/16 08:20
Hikma Pharmaceuticals (HIK) Initiated with a Buy at Citi
TipRanks · 07/16 06:15
Hikma Cancels More Shares as $250m Buyback Passes 10 Million Mark
TipRanks · 07/13 09:42
Weekly Report: what happened at HKMPF last week (0706-0710)?
Weekly Report · 07/13 09:12
Weekly Report: what happened at HKMPF last week (0629-0703)?
Weekly Report · 07/06 09:12
Hikma Advances $250m Share Buyback, Tightens Free-Float
TipRanks · 07/06 08:42
Weekly Report: what happened at HKMPF last week (0622-0626)?
Weekly Report · 06/29 09:12
Hikma Advances $250m Buyback, Cuts Share Count and Voting Free Float
TipRanks · 06/29 08:52
Hikma Pharmaceuticals (HIK) Receives a Buy from Deutsche Bank
TipRanks · 06/24 17:05
Barclays Sticks to Their Sell Rating for Hikma Pharmaceuticals (HIK)
TipRanks · 06/23 08:59
Hikma Advances $250m Buyback, Tightens Share Base
TipRanks · 06/22 12:18
Weekly Report: what happened at HKMPF last week (0615-0619)?
Weekly Report · 06/22 09:13
Weekly Report: what happened at HKMPF last week (0608-0612)?
Weekly Report · 06/15 09:13
Hikma Advances $250m Buyback, Cuts Share Count and Tightens Free Float
TipRanks · 06/15 08:43
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come
Seeking Alpha · 06/08 21:27
Weekly Report: what happened at HKMPF last week (0601-0605)?
Weekly Report · 06/08 09:12
More
Webull provides a variety of real-time HKMPF stock news. You can receive the latest news about Hikma Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HKMPF
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and non-licensed pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. It supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). It supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. It supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.